Skip to content

Study · Randomized controlled trial · 2026

5 results

A phase 1 evaluation of inhaled oxytocin: Physiologically-based pharmacokinetic model informed dosing of a novel heat-stable oxytocin delivery system.

Lambert P, Kirkpatrick CMJ, Marriott R, Chaudhuri SR, Polidori D, Remmerie B, McIntosh MP

British journal of clinical pharmacology4 Apr 2026Cited by 1 (Europe PMC)

PMID41934192 (opens in a new tab)PMCIDPMC13420879 (opens in a new tab)DOI10.1002/bcp.70544 (opens in a new tab)PepBankPUB-41934192
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy non-pregnant women, inhaled oxytocin 150 μg gave a Cmax of 77 pg/mL and an AUC0-inf of 2488 min.pg/mL.

    In plain wordsIn healthy non-pregnant women, inhaled oxytocin 150 μg gave a peak blood level of 77 pg/mL.

    Peptide
    Oxytocin
    Outcome
    Not applicableCmax and AUC0-inf of inhaled oxytocin 150 μg
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    150 μg · inhalationAs given in this study (human).

    Measurements

    Cmax
    77 pg/mL
    inhaled 150 μg
    AUC0-inf
    2488 min.pg/mL
    inhaled 150 μg

    Source sentences

    Summary
    with the 150 μg (Cmax = 77 pg/mL, AUC0-inf = 2488 min.pg/mL)
    2 context sentences
    Summary · context
    This was used to select the oxytocin dose range for a randomized, single-centre, partially single-blind, placebo-controlled, fixed-sequence phase 1 study in comparison to standard of care injectable doses in a part cross-over design.
    Summary · context
    Fifteen of 20 randomized participants completed the study.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy non-pregnant women, inhaled oxytocin 600 μg gave a Cmax of 398 pg/mL and an AUC0-inf of 14 792 min.pg/mL.

    In plain wordsIn healthy non-pregnant women, inhaled oxytocin 600 μg gave a peak blood level of 398 pg/mL.

    Peptide
    Oxytocin
    Outcome
    Not applicableCmax and AUC0-inf of inhaled oxytocin 600 μg
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    600 μg · inhalationAs given in this study (human).

    Measurements

    Cmax
    398 pg/mL
    inhaled 600 μg

    Source sentences

    Summary
    and 600 μg (Cmax = 398 pg/mL, AUC0-inf = 14 792 min.pg/mL) inhaled oxytocin doses
    2 context sentences
    Summary · context
    This was used to select the oxytocin dose range for a randomized, single-centre, partially single-blind, placebo-controlled, fixed-sequence phase 1 study in comparison to standard of care injectable doses in a part cross-over design.
    Summary · context
    Fifteen of 20 randomized participants completed the study.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy non-pregnant women, intramuscular oxytocin 10 IU gave a Cmax of 197 pg/mL and an AUC0-inf of 8560 min.pg/mL; the 150 μg and 600 μg inhaled doses bracketed these values.

    In plain wordsIn healthy non-pregnant women, injected oxytocin 10 IU gave a peak blood level of 197 pg/mL, between the two inhaled doses.

    Peptide
    Oxytocin
    Outcome
    Not applicableCmax and AUC0-inf of intramuscular oxytocin 10 IU
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 IU · intramuscularAs given in this study (human).

    Measurements

    Cmax
    197 pg/mL
    intramuscular 10 IU
    AUC0-inf
    8560 min.pg/mL
    intramuscular 10 IU

    Source sentences

    Summary
    the 10 IU intramuscular doses (Cmax = 197 pg/mL, AUC0-inf = 8560 min.pg/mL).
    2 context sentences
    Summary · context
    This was used to select the oxytocin dose range for a randomized, single-centre, partially single-blind, placebo-controlled, fixed-sequence phase 1 study in comparison to standard of care injectable doses in a part cross-over design.
    Summary · context
    Fifteen of 20 randomized participants completed the study.
  4. 04HumanRandomized controlled trialSafety outcome

    In healthy non-pregnant women, repeat dosing of inhaled oxytocin was well tolerated, with no significant treatment-related adverse events or clinical findings.

    In plain wordsIn healthy non-pregnant women, repeated inhaled oxytocin was well tolerated, with no significant treatment-related side effects reported.

    Peptide
    Oxytocin
    Outcome
    Not applicableTolerability and treatment-related adverse events of repeat inhaled dosing
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    150 μg to 900 μg · inhalationAs given in this study (human).

    Source sentences

    Summary
    Repeat dosing of inhaled oxytocin was well-tolerated, and no significant treatment-related adverse events or clinical findings were reported.
    3 context sentences
    Summary · context
    Participants received increasing inhaled oxytocin doses (150 μg, 300 μg, 600 μg and 900 μg) in single and/or repeat dose regimens.
    Summary · context
    This was used to select the oxytocin dose range for a randomized, single-centre, partially single-blind, placebo-controlled, fixed-sequence phase 1 study in comparison to standard of care injectable doses in a part cross-over design.
    Summary · context
    Fifteen of 20 randomized participants completed the study.

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 05Computer modelNot a test of Oxytocin aloneIn silicoPharmacokinetics

    The physiologically-based pharmacokinetic model predicted key pharmacokinetic parameters of inhaled oxytocin within two-fold of the observed values.

    In plain wordsA computer model predicted key blood-level measures of inhaled oxytocin to within two-fold of the values seen in volunteers.

    Peptide
    Oxytocin
    Outcome
    Not applicablePBPK model prediction of key PK parameters
    Study

    n: not reported in source

    PBPK model
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The PBPK model accurately predicted key PK parameters within two-fold of the observed values.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.